Amazon's Bezos leads new investment in AI data company Toloka
By Alexander Marrow
LONDON (Reuters) -Jeff Bezos' personal firm Bezos Expeditions is leading a $72-million investment in artificial intelligence data solutions company Toloka, which is looking to scale up its business, Toloka told Reuters on Wednesday.
Toloka, which helps train and evaluate AI models using a network of human experts and testers, is part of Nasdaq-listed AI infrastructure firm Nebius Group and has worked with Amazon, Microsoft and Anthropic.
Amsterdam-based Nebius emerged from a $5.4 billion deal, finalised last year, that split the domestic and international assets of Russian internet giant Yandex in the largest corporate exit from Russia since Moscow's 2022 invasion of Ukraine.
Toloka founder and CEO Olga Megorskaya said the Bezos-led strategic investment was a milestone that should accelerate the company's growth, particularly in the U.S. market, and support its development of products through human experts collaborating with AI agents.
"There will always be the need for control, verification, and help from human experts to ensure that the result is actually of high quality," Megorskaya told Reuters.
Before finalising the split from Yandex, Nebius would have struggled to secure external investment from the likes of Amazon founder Bezos due to sanctions prohibiting U.S. investments in Russia.
Chip giant Nvidia was among the investors in a $700 million private placement raised by Nebius late last year.
In addition to Bezos Expeditions, Mikhail Parakhin, CTO of Canadian e-commerce company Shopify, is participating in the investment, Nebius said, and will join Toloka's new board of directors as executive chairman.
Parakhin said he was excited to be joining Toloka at a time when the demand for world-class AI data expertise is more urgent than ever.
Bezos Expeditions did not immediately respond to a request for comment.
Nebius said it would continue to support Toloka as a shareholder, retaining a significant majority economic stake, but relinquishing majority voting control.
"The important thing about this round is that we gained the needed flexibility to operate independently," Megorskaya said.
She said Toloka anticipated another investment round in the future.
(Reporting by Alexander Marrow; Editing by Joe Bavier)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
JPMorgan lifts yuan forecast on easing tariff risks, de-dollarisation trend
LONDON (Reuters) -JPMorgan lifted its end-of-year forecast for China's onshore yuan spot price on Wednesday, citing moderating risks around the U.S. trade war and a broader global theme of so-called de-dollarisation. The U.S. investment bank said it was revising its dollar/yuan target to 7.15 yuan per dollar from 7.30, adding that it also expected a "gentle downtrend" to 7.10 by the middle of next year. The dollar was steady against the yuan at 7.1875 in European trading after U.S. and Chinese negotiators said they had agreed on a framework to get their countries' trade truce back on track following two days of talks in London. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Post
27 minutes ago
- New York Post
Nintendo Switch 2 smashes record as company's fastest-selling console
Japan's Nintendo said on Wednesday it had sold more than 3.5 million Switch 2 units in the first four days after its launch, making the console the company's fastest-selling gaming device to date. Last month, the Kyoto-based company forecast Switch 2 sales would reach 15 million during the current financial year ending next March. 'Fans around the world are showing their enthusiasm for Nintendo Switch 2 as an upgraded way to play at home and on the go,' Nintendo of America President and Chief Operating Officer Doug Bowser said in a statement. Advertisement 3 A person wearing a Luigi hat sits in line playing a Nintendo Switch, waiting to buy a Nintendo Switch 2 in New York City on June 4, 2025. REUTERS 3 A person holds a stack of Nintendo Switch 2 devices while restocking at Nintendo's store in Rockefeller Center on June 5, 2025. AP 3 A man shows off the Nintendo Switch 2 inside a Tokyo store on June 5, 2025. AFP via Getty Images Advertisement Nintendo has sold 152 million Switch devices since it was first launched in 2017, creating a games juggernaut with titles including 'The Legend of Zelda' and COVID-19 pandemic breakout hit 'Animal Crossing: New Horizons.' The more powerful second-generation version, which went on sale on June 5, bears many similarities with its predecessor but offers a larger screen and improved graphics. It is sold with titles including 'Mario Kart World.'
Yahoo
31 minutes ago
- Yahoo
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio